Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 52Hodgkin Disease 29Lymphoma 15Sarcoma 7Neoplasm Metastasis 7Uveal Melanoma 6Skin Neoplasms 6Neoplasms 5Leiomyosarcoma 5Solitary Fibrous Tumors 2Sarcoma, Synovial 2Neuroblastoma 2Hematologic Diseases 2HIV Infections 2Solid Tumor 1Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Melanoma Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Liposarcoma 1Kidney Neoplasms 1

Interventions

Fluorouracil 128Leucovorin 120Oxaliplatin 101Irinotecan 89Bevacizumab 55Cetuximab 44Capecitabine 40Folfox protocol 29Panitumumab 22Colonoscopy 17Chemotherapy, Adjuvant 16Floxuridine 15Early Intervention, Educational 15Erlotinib Hydrochloride 13Surveys and Questionnaires 11IFL protocol 11Counseling 11Celecoxib 11Immunohistochemistry 10Gemcitabine 10Psychiatric Rehabilitation 9Methods 8Magnetic Resonance Spectroscopy 8Gene Expression Profiling 8Exercise 8Dexamethasone 8sargramostim 7Sorafenib 7Radiotherapy 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colonic Neoplasms × Dacarbazine × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡